SCHEMBL20095877

SCHEMBL20095877

CN(CCF)C1CCCCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.42
HRH4 Q9H3N8 1/20 0.42
ADH1A P07327 4/20 0.38
ADH1C P00326 3/20 0.38
KDM4E B2RXH2 1/20 0.37
FAAH O00519 1/20 0.34
PHGDH O43175 1/20 0.34
MGLL Q99685 1/20 0.34
SIGMAR1 Q99720 2/20 0.34
ALDH1A1 P00352 2/20 0.34
ABCB11 O95342 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
AR P10275 1/20 0.34
CYP2D6 P10635 1/20 0.34
SLC6A2 P23975 1/20 0.34
PDE4A P27815 1/20 0.34
SLC6A4 P31645 1/20 0.34
SLC6A3 Q01959 1/20 0.34
KCNH2 Q12809 1/20 0.34
LMNA P02545 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20095943 0.86 HRH3 (0.40) HRH3HRH4ADH1AADH1CKDM4E
SCHEMBL22011094 0.84 HRH4 (0.33) HRH3HRH4ALDH1A1
SCHEMBL3186493 0.81 HRH3 (0.42) HRH3HRH4ADH1AADH1CKDM4E
Hydrochloric Acid SCHEMBL27567168 0.79 HRH4 (0.41) HRH3HRH4ADH1AADH1CKDM4E
Hydrochloric Acid SCHEMBL6897821 0.79 HRH4 (0.41) HRH3HRH4ADH1AADH1CKDM4E
SCHEMBL25921683 0.79 KDM4E (0.32) KDM4EALDH1A1
SCHEMBL24951938 0.78 HRH4 (0.39) HRH3HRH4ADH1AADH1CKDM4E
SCHEMBL9927904 0.78 HRH3 (0.44) HRH3HRH4ADH1AADH1CKDM4E
SCHEMBL10714608 0.78 HRH3 (0.44) HRH3HRH4ADH1AADH1CKDM4E
SCHEMBL5253027 0.78 ADH1A (0.52) HRH3HRH4ADH1AADH1CKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020142612-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH, INC. (US) 2020-07-09 WO disclosed
WO-2018072602-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2018-04-26 WO disclosed